Home » Stocks » ALXO

ALX Oncology Holdings, Inc. (ALXO)

Stock Price: $60.60 USD -1.11 (-1.80%)
Updated May 11, 2021 4:00 PM EDT - Market closed
Market Cap 2.39B
Revenue (ttm) 1.18M
Net Income (ttm) -50.94M
Shares Out 40.23M
EPS (ttm) -2.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $60.60
Previous Close $61.71
Change ($) -1.11
Change (%) -1.80%
Day's Open 60.03
Day's Range 59.25 - 64.17
Day's Volume 161,725
52-Week Range 28.01 - 117.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Alx Oncology Holding sees its Relative Strength Rating enter the 80-plus level. The post Alx Oncology Holding Meets 80-Plus Relative Strength Rating Benchmark appeared first on Investor's Business Daily.

1 week ago - Investors Business Daily

Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer ...

2 weeks ago - GlobeNewsWire

BURLINGAME, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 chec...

1 month ago - GlobeNewsWire

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.

Other stocks mentioned: ALC, CURI, SMTC, UPST
1 month ago - CNBC

BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

1 month ago - GlobeNewsWire

BURLINGAME, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

2 months ago - GlobeNewsWire

ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 check...

4 months ago - GlobeNewsWire

ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.

4 months ago - Seeking Alpha

ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only having a single...

4 months ago - Seeking Alpha

BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkp...

4 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: ATH, BH, GDYN, LXRX, SNEX, SONA, UEPS ...
4 months ago - Benzinga

BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoi...

4 months ago - GlobeNewsWire

BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoi...

5 months ago - GlobeNewsWire

BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoi...

5 months ago - GlobeNewsWire

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma... [Read more...]

Industry
Biotechnology
IPO Date
Jul 17, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ALXO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price forecast is 98.43, which is an increase of 62.43% from the latest price.

Price Target
$98.43
(62.43% upside)
Analyst Consensus: Strong Buy